Head and neck diseases

Summary

The Head and Neck research group, as part of its line of cancer research, studies new therapeutic targets and predictive biomarkers of response to chemotherapy, radiotherapy and immunotherapy, the role of the human papilloma virus (HPV) and the differential management of HPV+ tumours, transoral treatment of laryngeal cancer with CO2 laser and robotic surgery, reconstructive surgery and pharyngeal rehabilitation of laryngectomised patients

406 Publications

Strategic lines

To define a more precise and personalised treatment by defining new molecular prognostic and predictive tools for patients with squamous-cell carcinoma (SCC).
To define markers of detection and prognosis of HPV-induced oropharyngeal SCC, in order to obtain an early diagnosis and personalised treatment for this group of patients.
To find treatment biomarkers for induced late toxicity, in order to prevent and treat this appropriately.
To implement the use of immunotherapy for oropharyngeal SCC.
To improve transoral head and neck surgery to lead to an improvement in quality of life, with safe results.

Selected Publications

- Piulats JM, Espinosa E, Merino LD, Varela M, Carrion LA, Martin Algarra S, Castro RL, Curiel T, Rodriguez Abreu D, Redrado M, Goma M, Rullan AJ, Gonzalez AC, Berrocal Jaime A. Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586-598. doi:10.1200/JCO.20.00550. IF:44,54.

- Guigay J, Auperin A, Fayette J, Saada Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus Clement C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R, G, A, TTCC, UniCancer Head Neck GRP. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-475. doi:10.1016/S1470-2045(20)30755-5. IF:41,32.

- Oliva M, Chepeha D, Araujo DV, Diaz Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, Hansen AR, Hope A, Goldstein D, Weinreb I, Smith S, Perez Ordonez B, Irish J, Torti D, Bruce JP, Wang B, Fortuna A, Pugh TJ, Der Torossian H, Shazer R, Attanasio N, Au QY, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu LL. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021;9(10):doi:10.1136/jitc-2021-003476. IF:13,75.

- Oliva M, Schneeberger PHH, Rey V, Cho M, Taylor R, Hansen AR, Taylor K, Hosni A, Bayley A, Hope AJ, Bratman SV, Ringash J, Singh S, Weinreb I, Perez Ordoñez B, Chepeha D, Waldron J, Xu W, Guttman D, Siu LL, Coburn B, Spreafico A. Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). Br. J. Cancer. 2021;124(9):1543-1551. doi:10.1038/s41416-020-01253-1. IF:7,64.

- Arribas L, Plana M, Taberna M, Sospedra M, Vilarino N, Oliva M, Pallares N, Tampan A, Del Rio LM, Mesia R, Baracos V. Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Oncol. 2021;11699668-699668. doi:10.3389/fonc.2021.699668. IF:6,24.

Selected Projects

- 21FIS004. CONTRATOS PREDOCTORALES DE FORMACION EN INVESTIGACION EN SALUD (PFIS). (FI20/00103). ISCIII. 2021-2024. IP:MESIA NIN,RICARD.

- 21FIS023. CONTRATOS RIO HORTEGA. (CM20/00120). ISCIII. 2021-2022. IP:MESIA NIN,RICARD.

- 21DPS001. PRESERVE: AI for new signatures and models for tailored organ preservation approaches in laryngeal and hypopharyngeal cancer. (SLD043/20/000001). ASST SPEDALI CIVILI DI BRESCIA (ASST-SC ); ATHENS TECHNOLOGY CENTER (ATC); DIR.GEN.SALUT PUBLICA, DEP.SALUT GE; FUNDACIO IDIBELL; ISTITUTO EUROPEO DI ONCOLOGIA; UNIVERSITY OF LEIPZIG; UNIVERSITY OF OSLO (UIO). 2021-2023. IP:MESIA NIN,RICARD.

- 20PSJ025. Papel de la microbiota oral como biomarcador en el cáncer de orofaringe VPH-relacionado y no relacionado. SOCIEDAD ESPAÑOLA DE ONCOLOGIA MEDICA. 2020-2022. IP:TABERNA SANZ,MIREN.

- 20FIS005. Valor predictivo y pronóstico de la composición corporal y el hábito tabáquico en pacientes de cáncer de orofaringe según su asociación al virus del papiloma humano. (PI19/00363). ISCIII. 2020-2022. IP:MESIA NIN,RICARD.

More Information